Sheelagh is CSO of the Dundee based biotech company, Ubiquigent, and has over 25 years’ experience in oncology drug discovery and development. She joined Ubiquigent in 2018 as Head of Biology taking responsibility for the company’s operations in Dundee becoming CSO in 2021. During this period, Sheelagh has grown the Ubiquigent team and laboratory operations, expanded the suite of assays within the company’s Drug Discovery Screening Platform, managed client relationships and supported the growth in the revenue-generating services and the development of an IP portfolio of novel deubiquitylase (DUB) enzyme modulators.Whilst in her previous roles, Sheelagh gained significant expertise in drug discovery and development, mainly in oncology, but also spanning autoimmune/inflammation, diabetes and rare diseases, working with international research groups, clinical investigators and KOLs. She looks forward to leveraging her experience in translational research & drug development alongside Ubiquigent’s expertise in modulating the deubiquitinase (DUB) enzyme family to exploit the ubiquitin-proteasome pathway to address unmet medical needs.Sheelagh holds a BSc Hons in Molecular Biology from the University of Edinburgh and a PhD in Medicine from the Beatson Institute for Cancer Research, affiliated to the University of Glasgow.